Substituted 6-(4-hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors

US9133181B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Stephanie Hachtel · Frankfurt am Main, DE
• Christian Schoenau · Hochheim, DE
• Matthias Loehn · Frankfurt am Main, DE
• Oliver Plettenburg · Kelkheim, DE
• Stefania PFEIFFER-MAREK · Frankfurt, DE
• Alexander Schiffer · Frankfurt am Main, DE
• Holger Gaul · Runkel, DE
• Aimo Kannt · Dreieich, DE
• Juergen Dedio · Frankfurt, DE
• Angela Dudda · Frankfurt, DE

Key dates

• Filing date: Nov 10, 2014
• Grant date: Sep 15, 2015
• Expiry date: Nov 10, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I,in which R1, R2, R3, R4, R5 and R6 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.